EUVIMEDEUVIMED entdecken
Editorial

One and Done — Single-Dose Zoledronic Acid in Early-Stage Breast Cancer

Neelima Vidula

NEJM Evidence · 26.05.2026 · 5 (6)

DOI: 10.1056/evide2600083 ↗

Kurz gefasst

Editorial in der Zeitschrift NEJM Evidence, erschienen am 26.05.2026. Verfasst von Neelima Vidula. Beteiligte Einrichtung: Massachusetts General Hospital, Harvard Medical School, Boston, MA. Die Arbeit nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Zitieren

APA

Vidula, N. (2026). One and Done — Single-Dose Zoledronic Acid in Early-Stage Breast Cancer. NEJM Evidence, 5(6). https://doi.org/10.1056/evide2600083

Vancouver

Vidula N. One and Done — Single-Dose Zoledronic Acid in Early-Stage Breast Cancer. NEJM Evidence. 2026;5(6). doi:10.1056/evide2600083

BibTeX
@article{Vidula2026,
  author = {Vidula, Neelima},
  title = {One and Done — Single-Dose Zoledronic Acid in Early-Stage Breast Cancer},
  journal = {NEJM Evidence},
  year = {2026},
  volume = {5},
  number = {6},
  doi = {10.1056/evide2600083}
}
Kostenlos starten →